Open Access

KIF22 promotes bladder cancer progression by activating the expression of CDCA3

  • Authors:
    • Kai Li
    • Song Li
    • Shuai Tang
    • Minghao Zhang
    • Zhen Ma
    • Qi Wang
    • Fangmin Chen
  • View Affiliations

  • Published online on: October 7, 2021     https://doi.org/10.3892/ijmm.2021.5044
  • Article Number: 211
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bladder cancer is a common malignant tumor of the urinary system and is associated with a high morbidity and mortality, due to the difficulty in the accurate diagnosis of patients with early‑stage bladder cancer and the lack of effective treatments for patients with advanced bladder cancer. Thus, novel therapeutic targets are urgently required for this disease. Kinesin family member 22 (KIF22) is a kinesin‑like DNA binding protein belonging to kinesin family, and is involved in the regulation of mitosis. KIF22 has also been reported to promote the progression of several types of cancer, such as breast cancer and melanoma. The present study demonstrates the high expression of KIF22 in human bladder cancer tissues. KIF22 was found to be associated with clinical features, including clinical stage (P=0.003) and recurrence (P=0.016), and to be associated with the prognosis of patients with bladder cancer. Furthermore, it was found that KIF22 silencing inhibited the proliferation of bladder cancer cells in vitro and tumor progression in mice. Additionally, it was noted that KIF22 transcriptionally activated cell division cycle‑associated protein 3 expression, which was also confirmed in tumors in mice. Taken together, the present study investigated the molecular mechanisms underlying the promotion of bladder cancer by KIF22 and provide a novel therapeutic target for the treatment of bladder cancer.
Introduction
View Figures
View References

Related Articles

Journal Cover

December-2021
Volume 48 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li K, Li S, Tang S, Zhang M, Ma Z, Wang Q and Chen F: KIF22 promotes bladder cancer progression by activating the expression of CDCA3. Int J Mol Med 48: 211, 2021
APA
Li, K., Li, S., Tang, S., Zhang, M., Ma, Z., Wang, Q., & Chen, F. (2021). KIF22 promotes bladder cancer progression by activating the expression of CDCA3. International Journal of Molecular Medicine, 48, 211. https://doi.org/10.3892/ijmm.2021.5044
MLA
Li, K., Li, S., Tang, S., Zhang, M., Ma, Z., Wang, Q., Chen, F."KIF22 promotes bladder cancer progression by activating the expression of CDCA3". International Journal of Molecular Medicine 48.6 (2021): 211.
Chicago
Li, K., Li, S., Tang, S., Zhang, M., Ma, Z., Wang, Q., Chen, F."KIF22 promotes bladder cancer progression by activating the expression of CDCA3". International Journal of Molecular Medicine 48, no. 6 (2021): 211. https://doi.org/10.3892/ijmm.2021.5044